Substantial evidence indicates that TANs with a protumor phenotype attenuate the proliferation and cytotoxicity of effector T cells and contribute to resistance to ICIs.[35, 36] Therefore, targeting DTX2 might increase the efficacy of anti‐PD‐1 antibody therapy in HCC. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.